AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28129518 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 61
Study 28129518 — intervention group
Group type: COMPARATOR
Intervention: Conventional shoes
Number of subjects: 61
Study 25595308 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 80
Study 25595308 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid therapy (Control)
Number of subjects: 80
Study 23750460 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral treatment based on exposure exercises (ICBT)
Number of subjects: 195
Study 23750460 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered stress management (ISM)
Number of subjects: 195
Study 21915490 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (12-week stimulation and psychoeducational program, administered twice a week during 6.5-hour gatherings)
Number of subjects: 41
Study 21915490 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program
Number of subjects: 41
Study 21915490 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list for future intervention)
Number of subjects: 41
Study 19589303 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR total ankle replacement (Pivotal Study)
Number of subjects: 158
Study 19589303 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR total ankle replacement (Continued Access Group)
Number of subjects: 158
Study 19589303 — intervention group
Group type: COMPARATOR
Intervention: Ankle fusion (Pivotal Study)
Number of subjects: 158
Study 17036357 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR performed on 51 patients (42.9%) at a mean of 2.7+/‐3.1 days after stent implantation (CMR+ group)
Number of subjects: 119
Study 17036357 — intervention group
Group type: COMPARATOR
Intervention: Control group (CMR- group) with 68 patients (57.1%)
Number of subjects: 119
Study 12572939 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-omega (2.5 million units/kg)
Number of subjects: 94
Study 12572939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 12572939 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-omega (2.5 million units/kg) in unvaccinated cohort
Number of subjects: 94
Study 12572939 — intervention group
Group type: COMPARATOR
Intervention: Placebo in unvaccinated cohort
Number of subjects: 94
Study 11127852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 140
Study 11127852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 9485969 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 30
Study 9485969 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 30
Study 9485969 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 30
Study 9485969 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant women in right lateral position
Number of subjects: 30
Study 16358395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (83.5 +/- 3.6% of total energy)
Number of subjects: 7
Study 16358395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (83.1 +/- 3.7% of total energy)
Number of subjects: 7
Study 16358395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 7
Study 16358395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 7
Study 3391420 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery
Number of subjects: 192
Study 3391420 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 192
Study 30450213 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) on a cycle ergometer, thrice weekly for 8 weeks
Number of subjects: 40
Study 30450213 — intervention group
Group type: COMPARATOR
Intervention: Weekly contact with investigators
Number of subjects: 40
Study 27214263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking with poles (WP)
Number of subjects: 17
Study 27214263 — intervention group
Group type: COMPARATOR
Intervention: Normal Walking without poles (NP)
Number of subjects: 17
Study 25620607 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage electrical stimulation (HVES)
Number of subjects: 15
Study 25620607 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 15
Study 25620607 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous short wave diathermy
Number of subjects: 15
Study 23877339 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m², 2-5 min intravenous on days 1 and 8)
Number of subjects: 104
Study 23877339 — intervention group
Group type: COMPARATOR
Intervention: Ixabepilone (40 mg/m², 3 h intravenous on day 1)
Number of subjects: 104
Study 19919966 — intervention group
Group type: EXPERIMENTAL
Intervention: Home orthostatic training (HOT) for 40 min daily for 6 months
Number of subjects: 22
Study 19919966 — intervention group
Group type: COMPARATOR
Intervention: Sham training for 10 min daily for 6 months
Number of subjects: 22
Study 18426147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (NS) plus loratadine, 200 microg + 10 mg
Number of subjects: 702
Study 18426147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (NS), 200 microg
Number of subjects: 702
Study 18426147 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg
Number of subjects: 702
Study 18426147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study 16682384 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel 300 mg, and Tirofiban)
Number of subjects: 328
Study 16682384 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin, clopidogrel 600 mg)
Number of subjects: 328
Study 16682384 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy
Number of subjects: 328
Study 16682384 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 328
Study 16682384 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 328
Study 22186694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR 30 mg injection once every 4 weeks for 6 doses (n = 35)
Number of subjects: 70
Study 9791789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare sonic toothbrush
Number of subjects: 30
Study 9791789 — intervention group
Group type: EXPERIMENTAL
Intervention: Interplak counterrotational mechanical toothbrush
Number of subjects: 30
Study 9791789 — intervention group
Group type: COMPARATOR
Intervention: Control (no brushing)
Number of subjects: 30
Study 7617237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 3 mu/kg/min, started before anesthesia and modulated during the operation based on monitoring values.
Number of subjects: 186
Study 7617237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dobutamine infusion), underwent the same anesthesiological procedure without receiving the drug.
Number of subjects: 186
Study 1978487 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release (CR) 400 mg once daily
Number of subjects: 24
Study 1978487 — intervention group
Group type: COMPARATOR
Intervention: Immediate release (IR) 200 mg twice daily
Number of subjects: 24
Study 629176 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory examinations
Number of subjects: 63
Study 629176 — intervention group
Group type: COMPARATOR
Intervention: Written examinations
Number of subjects: 63
Study 629176 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory and written examinations
Number of subjects: 63
Study 6818039 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordemethyldiazepam (19.25 micrograms/kg)
Number of subjects: 11
Study 6818039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6818039 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordemethyldiazepam (Cl‐DMDZ)
Number of subjects: 11
Study 31002399 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of autologous, leukoreduced RBCs after 1, 2, 3, 4, 5, or 6 weeks of storage
Number of subjects: 52
Study 31002399 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium‐99m‐labeled RBCs infused
Number of subjects: 52
Study 31002399 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium‐51 PTR method
Number of subjects: 52
Study 29401353 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice; full-dose (two 20-min sessions per day) and half-dose (one 20-min session per day) groups.
Number of subjects: 46
Study 29401353 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice; full-dose group vs half-dose group.
Number of subjects: 46
Study 29401353 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice; assessed at 30 days post-intervention.
Number of subjects: 46
Study 29401353 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice; assessed at 90 days post-intervention.
Number of subjects: 46
Study 27384031 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec and insulin aspart (IDegAsp)
Number of subjects: 0
Study 24476772 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose (Gal)
Number of subjects: 10
Study 24476772 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (Glu)
Number of subjects: 10
Study 24476772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22427850 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation
Number of subjects: 640
Study 22427850 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in anemic mothers
Number of subjects: 640
Study 22427850 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in undernourished mothers
Number of subjects: 640
Study 19778808 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (6.25-25 microg daily)
Number of subjects: 54
Study 19778808 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 54
Study 17643226 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Number of subjects: 21
Study 17643226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral computed tomographic angiography (CT‐a)
Number of subjects: 21
Study 17643226 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG and CT‐a combined (E+C+)
Number of subjects: 21
Study 17643226 — intervention group
Group type: COMPARATOR
Intervention: EEG only (E+C(‐))
Number of subjects: 21
Study 15908661 — intervention group
Group type: EXPERIMENTAL
Intervention: GemOx (gemcitabine 1 g/m2 as a 100‐minute infusion on day 1 and oxaliplatin 100 mg/m2 as a 2‐hour infusion on day 2 every 2 weeks)
Number of subjects: 326
Study 15908661 — intervention group
Group type: COMPARATOR
Intervention: Gem (gemcitabine 1 g/m2 as a weekly 30‐minute infusion)
Number of subjects: 326
Study 12039487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 0
Study 12039487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 5 microM (in vitro)
Number of subjects: 0
Study 9617916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (DA agonist)
Number of subjects: 0
Study 9617916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (serotonin agonist)
Number of subjects: 0
Study 9617916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7716629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractors
Number of subjects: 686
Study 7716629 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic physicians
Number of subjects: 686
Study 7716629 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 686
Study 2776043 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical abuse scenario
Number of subjects: 144
Study 2776043 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect scenario
Number of subjects: 144
Study 2776043 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender of subjects
Number of subjects: 144
Study 2776043 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of subjects
Number of subjects: 144
Study 2776043 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of mistreatment
Number of subjects: 144
Study 144842 — intervention group
Group type: EXPERIMENTAL
Intervention: SH B 209 AB (antiandrogen preparation containing cyproterone acetate)
Number of subjects: 88
Study 144842 — intervention group
Group type: COMPARATOR
Intervention: Neogynon (ovulation inhibitor with no antiandrogenic effect)
Number of subjects: 88
Study 30563431 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training)
Number of subjects: 42
Study 30563431 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (high-intensity interval training)
Number of subjects: 42
Study 30563431 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT (moderate-intensity continuous training)
Number of subjects: 42
Study 28866652 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day folic acid
Number of subjects: 45
Study 28866652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day folic acid
Number of subjects: 45
Study 26521569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint injection of nerve growth factor (NGF), 0.5 mL each acupoint, once a day for 7 days, 3 sessions total
Number of subjects: 61
Study 26521569 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drop of citicoline sodium and intramuscular injection of NGF, treatment for 7 days, 3 sessions total
Number of subjects: 61
Study 26521569 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior determination scores
Number of subjects: 61
Study 26521569 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 61
Study 23793385 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoelastic splints
Number of subjects: 25
Study 23793385 — intervention group
Group type: COMPARATOR
Intervention: Traditional fixed-angle braces
Number of subjects: 25
Study 21041710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions)
Number of subjects: 359
Study 21041710 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 359
Study 21041710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant whole-brain radiotherapy (WBRT)
Number of subjects: 359
Study 19185560 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN+D5600 (alendronate + 5600 IU vitamin D3)
Number of subjects: 0
Study 19185560 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN+D2800 (alendronate + 2800 IU vitamin D3)
Number of subjects: 0
Study 16897661 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Treatment Interruption (STI)
Number of subjects: 97
Study 16897661 — intervention group
Group type: COMPARATOR
Intervention: ALVAC-HIV vCP1452 immunization
Number of subjects: 97
Study 16897661 — intervention group
Group type: EXPERIMENTAL
Intervention: STI and ALVAC-HIV vCP1452 immunization
Number of subjects: 97
Study 15633813 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on the extra 1 point (yintang) for 15 minutes
Number of subjects: 50
Study 15633813 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture on the control point (2 cm lateral to the end of the right eyebrow) for 15 minutes
Number of subjects: 50
Study 15633813 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on the extra 1 point (yintang)
Number of subjects: 50
Study 15633813 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture on the control point (2 cm lateral to the end of the right eyebrow)
Number of subjects: 50
Study 11818305 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive sites (programs with incentives)
Number of subjects: 2402
Study 11818305 — intervention group
Group type: COMPARATOR
Intervention: No-incentive sites (programs without incentives)
Number of subjects: 2402
Study 11818305 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 2402
Study 11818305 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive sites
Number of subjects: 2402
Study 11818305 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone counseling
Number of subjects: 2402
Study 11818305 — intervention group
Group type: EXPERIMENTAL
Intervention: Group programs
Number of subjects: 2402
Study 9658344 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression with calcific deposits left untouched
Number of subjects: 50
Study 7651473 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblast transfer (110 million cells injected once a month for six months)
Number of subjects: 12
Study 7651473 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblast transfer
Number of subjects: 12
Study 7651473 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (control)
Number of subjects: 12
Study 2487532 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of ibopamine
Number of subjects: 11
Study 2487532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 355879 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy and intermittent positive-pressure breathing with racemic epinephrine every four hours
Number of subjects: 54
Study 355879 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without chest physiotherapy and intermittent positive-pressure breathing)
Number of subjects: 54
Study 31595716 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look procedure
Number of subjects: 51
Study 31595716 — intervention group
Group type: COMPARATOR
Intervention: Transoral surgery (TOS) alone
Number of subjects: 51
Study 28872917 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (MCI-186)
Number of subjects: 0
Study 28872917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27046443 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence angiography (ICG-FA) with SPY Elite
Number of subjects: 95
Study 27046443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICG-FA images viewed)
Number of subjects: 95
Study 27046443 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin/subcutaneous hypoperfusion on ICG-FA
Number of subjects: 95
Study 27046443 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap modification after viewing ICG-FA images
Number of subjects: 95
Study 25044423 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin capsules
Number of subjects: 8
Study 25044423 — intervention group
Group type: COMPARATOR
Intervention: Glyburide therapy
Number of subjects: 8
Study 21542122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous n-acetylcysteine (1,200 mg bolus followed by 200 mg/hr for 24 hr; n = 206)
Number of subjects: 398
Study 21542122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 192)
Number of subjects: 398
Study 21542122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous n-acetylcysteine
Number of subjects: 398
Study 21542122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 19595348 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic2000 Forte (n=399)
Number of subjects: 795
Study 19595348 — intervention group
Group type: COMPARATOR
Intervention: Control (n=396)
Number of subjects: 795
Study 17322148 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-706
Number of subjects: 130
Study 15080606 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure valve device
Number of subjects: 153
Study 15080606 — intervention group
Group type: COMPARATOR
Intervention: Standard device
Number of subjects: 153
Study 11467630 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg erythromycin (Er50)
Number of subjects: 10
Study 11467630 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg erythromycin (Er100)
Number of subjects: 10
Study 11467630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 11467630 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10
Study 9812643 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianzhen tablet
Number of subjects: 72
Study 9812643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7959083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C, 250 mg twice daily
Number of subjects: 48
Study 7959083 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one capsule twice daily
Number of subjects: 48
Study 3652479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg orally at 2200 and 2400 h)
Number of subjects: 5
Study 3652479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29617737 — intervention group
Group type: COMPARATOR
Intervention: 200 µg/kg ivermectin
Number of subjects: 292
Study 29617737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 29617737 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 µg/kg ivermectin
Number of subjects: 292
Study 26826329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk dentine replacement material
Number of subjects: 72
Study 26826329 — intervention group
Group type: COMPARATOR
Intervention: Incrementally placed hybrid composite
Number of subjects: 72
Study 24913256 — intervention group
Group type: EXPERIMENTAL
Intervention: EGA‐Cycling (Environmental Google Street View Based Audit ‐ Cycling to school)
Number of subjects: 52
Study 24913256 — intervention group
Group type: EXPERIMENTAL
Intervention: EGA‐Cycling
Number of subjects: 52
Study 24913256 — intervention group
Group type: COMPARATOR
Intervention: On‐site assessments
Number of subjects: 52
Study 22302652 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV screening
Number of subjects: 877
Study 22302652 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination
Number of subjects: 877
Study 22302652 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of HBV, family and physician recommendations
Number of subjects: 877